Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Breast Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Solid Tumor (16911
)
HER2 Negative Breast Cancer (539
)
HER2 Positive Breast Cancer (509
)
Triple Negative Breast Cancer (362
)
Hormone Receptor Positive Breast Cancer (335
)
Estrogen Receptor Positive Breast Cancer (220
)
Male Breast Cancer (10
)
Hormone Receptor Negative Breast Cancer (4
)
Solid Tumor (16911
)
HER2 Negative Breast Cancer (539
)
HER2 Positive Breast Cancer (509
)
Triple Negative Breast Cancer (362
)
Hormone Receptor Positive Breast Cancer (335
)
Estrogen Receptor Positive Breast Cancer (220
)
Male Breast Cancer (10
)
Hormone Receptor Negative Breast Cancer (4
)
›
Associations
(2427)
News
Trials
VERI cancer hierarchy
Reset Filters
BRCA mutation
HER2 Negative Breast Cancer
BRCA mutation
HER2 Negative Breast Cancer
rivoceranib + fluzoparib
Sensitive: B - Late Trials
NAVLIN DAILY - 3 weeks (New B)
rivoceranib + fluzoparib
Sensitive
:
B
NAVLIN DAILY - 3wk
rivoceranib + fluzoparib
Sensitive: B - Late Trials
NAVLIN DAILY - 3 weeks
rivoceranib + fluzoparib
Sensitive
:
B
NAVLIN DAILY - 3 weeks - (New B)
PD-L1 expression
Triple Negative Breast Cancer
PD-L1 expression
Triple Negative Breast Cancer
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + tucatinib
Sensitive: A1 - Approval
trastuzumab + tucatinib
Sensitive
:
A1
trastuzumab + tucatinib
Sensitive: A1 - Approval
trastuzumab + tucatinib
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: A1 - Approval
trastuzumab + pertuzumab
Sensitive
:
A1
trastuzumab + pertuzumab
Sensitive: A1 - Approval
trastuzumab + pertuzumab
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
margetuximab
Sensitive: A1 - Approval
margetuximab
Sensitive
:
A1
margetuximab
Sensitive: A1 - Approval
margetuximab
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
No biomarker
Breast Cancer
No biomarker
Breast Cancer
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive: A1 - Approval
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive
:
A1
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive: A1 - Approval
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive: A1 - Approval
ado-trastuzumab emtansine
Sensitive
:
A1
ado-trastuzumab emtansine
Sensitive: A1 - Approval
ado-trastuzumab emtansine
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
No biomarker
Breast Cancer
No biomarker
Breast Cancer
TAC
Sensitive: A1 - Approval
TAC
Sensitive
:
A1
TAC
Sensitive: A1 - Approval
TAC
Sensitive
:
A1
HR positive
HER2 Positive Breast Cancer
HR positive
HER2 Positive Breast Cancer
neratinib
Sensitive: A1 - Approval
neratinib
Sensitive
:
A1
neratinib
Sensitive: A1 - Approval
neratinib
Sensitive
:
A1
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
sacituzumab govitecan-hziy
Sensitive: A1 - Approval
sacituzumab govitecan-hziy
Sensitive
:
A1
sacituzumab govitecan-hziy
Sensitive: A1 - Approval
sacituzumab govitecan-hziy
Sensitive
:
A1
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
palbociclib
Sensitive: A1 - Approval
palbociclib
Sensitive
:
A1
palbociclib
Sensitive: A1 - Approval
palbociclib
Sensitive
:
A1
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
ribociclib
Sensitive: A1 - Approval
ribociclib
Sensitive
:
A1
ribociclib
Sensitive: A1 - Approval
ribociclib
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
pertuzumab/trastuzumab/hyaluronidase-zzxf
Sensitive: A1 - Approval
pertuzumab / trastuzumab / hyaluronidase-zzxf
Sensitive
:
A1
pertuzumab/trastuzumab/hyaluronidase-zzxf
Sensitive: A1 - Approval
pertuzumab / trastuzumab / hyaluronidase-zzxf
Sensitive
:
A1
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
alpelisib
Sensitive: A1 - Approval
alpelisib
Sensitive
:
A1
alpelisib
Sensitive: A1 - Approval
alpelisib
Sensitive
:
A1
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
abemaciclib
Sensitive: A1 - Approval
abemaciclib
Sensitive
:
A1
abemaciclib
Sensitive: A1 - Approval
abemaciclib
Sensitive
:
A1
PD-L1 expression
Triple Negative Breast Cancer
PD-L1 expression
Triple Negative Breast Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
HER-2 amplification
Hormone Receptor Positive Breast Cancer
HER-2 amplification
Hormone Receptor Positive Breast Cancer
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
HER-2 amplification
HER2 Positive Breast Cancer
HER-2 amplification
HER2 Positive Breast Cancer
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
HER-2 overexpression
HER2 Positive Breast Cancer
HER-2 overexpression
HER2 Positive Breast Cancer
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
HER-2 amplification
Hormone Receptor Positive Breast Cancer
HER-2 amplification
Hormone Receptor Positive Breast Cancer
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
HER-2 amplification
HER2 Positive Breast Cancer
HER-2 amplification
HER2 Positive Breast Cancer
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
HER-2 overexpression
HER2 Positive Breast Cancer
HER-2 overexpression
HER2 Positive Breast Cancer
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
HER-2 amplification
Hormone Receptor Positive Breast Cancer
HER-2 amplification
Hormone Receptor Positive Breast Cancer
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
HER-2 amplification
HER2 Positive Breast Cancer
HER-2 amplification
HER2 Positive Breast Cancer
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
HER-2 overexpression
HER2 Positive Breast Cancer
HER-2 overexpression
HER2 Positive Breast Cancer
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
HER-2 amplification
Hormone Receptor Positive Breast Cancer
HER-2 amplification
Hormone Receptor Positive Breast Cancer
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
HER-2 amplification
HER2 Positive Breast Cancer
HER-2 amplification
HER2 Positive Breast Cancer
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login